Wasatch Advisors LP Decreases Holdings in Intellia Therapeutics, Inc. $NTLA

Wasatch Advisors LP trimmed its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 51.3% in the second quarter, HoldingsChannel reports. The fund owned 127,649 shares of the company’s stock after selling 134,215 shares during the period. Wasatch Advisors LP’s holdings in Intellia Therapeutics were worth $2,160,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in NTLA. Oppenheimer & Co. Inc. raised its position in Intellia Therapeutics by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after purchasing an additional 808 shares during the period. Comerica Bank boosted its position in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the period. PNC Financial Services Group Inc. boosted its position in Intellia Therapeutics by 36.4% during the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock valued at $46,000 after buying an additional 948 shares during the period. Wealthfront Advisers LLC grew its stake in shares of Intellia Therapeutics by 7.6% during the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after buying an additional 1,018 shares during the last quarter. Finally, Benjamin Edwards Inc. grew its stake in shares of Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after buying an additional 1,126 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Trading Up 0.6%

Intellia Therapeutics stock opened at $12.09 on Thursday. The firm has a market cap of $1.69 billion, a P/E ratio of -3.60 and a beta of 1.81. Intellia Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $28.25. The firm has a 50-day moving average of $13.57 and a 200-day moving average of $13.44.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.80). The company had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.Intellia Therapeutics’s revenue was down 46.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.98) EPS. Research analysts forecast that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the transaction, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. The trade was a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on NTLA. Sanford C. Bernstein boosted their target price on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Wedbush raised their price target on Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. Leerink Partners set a $35.00 price target on Intellia Therapeutics in a research note on Monday, April 27th. Wall Street Zen downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eight have issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $21.15.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.